Margerison E S, Maguire M, Pillay D, Cane P, Elston R C
GlaxoSmithKline, Gunnels Wood Road, Stevenage SG1 2NY, UK.
J Antimicrob Chemother. 2008 Apr;61(4):786-91. doi: 10.1093/jac/dkm545. Epub 2008 Feb 4.
The identification and in vitro characterization of novel protease mutations strongly associated with known protease resistance mutations.
The association between pairs of protease amino acid substitutions was identified using a database of protease sequences derived from protease inhibitor-experienced patients (n = 803). In vitro characterization included drug susceptibility and viral replication studies performed on recombinant viruses harbouring site-directed mutations.
The K55R mutation, which is not a natural polymorphism, was identified to be strongly associated with protease mutations M46I/L and to a lesser extent L24I, I54V and V82A/T/S/F. In vitro characterization of the K55R substitution indicated a primary role for this substitution in increasing replicative capacity in the presence of specific protease mutations.
The K55R mutation is a secondary drug resistance mutation that can improve viral replication capacity in the presence of other primary protease mutations.
鉴定与已知蛋白酶抗性突变密切相关的新型蛋白酶突变并进行体外特性分析。
利用来自有蛋白酶抑制剂治疗经验患者的蛋白酶序列数据库(n = 803)确定蛋白酶氨基酸替代对之间的关联。体外特性分析包括对携带定点突变的重组病毒进行药物敏感性和病毒复制研究。
非天然多态性的K55R突变被确定与蛋白酶突变M46I/L密切相关,与L24I、I54V和V82A/T/S/F的相关性较弱。K55R替代的体外特性分析表明,在存在特定蛋白酶突变的情况下,该替代在增加复制能力方面起主要作用。
K55R突变是一种继发性耐药突变,在存在其他主要蛋白酶突变的情况下可提高病毒复制能力。